<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278070</url>
  </required_header>
  <id_info>
    <org_study_id>HE 50/05</org_study_id>
    <nct_id>NCT00278070</nct_id>
  </id_info>
  <brief_title>Metronomic Oral Vinorelbine in Patients With Metastatic Tumors</brief_title>
  <official_title>Metronomic Vinorelbine in Patients With Metastatic Tumors: Phase II Translational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ioannina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three
      different doses (30 or 40 or 50 mg). Vinorelbine will be administered orally at a metronomic
      schedule three times a week: on Monday, Wednesday and Friday.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to define the biologically optimal dose of vinorelbine when
      administered at a metronomic dosing schema. [Metronomic chemotherapy refers to the close,
      regular administration of minimally toxic doses of cytotoxic drugs, with minimal or no
      drug-free breaks, over prolonged periods]. Patients with recurrent or metastatic solid tumors
      are randomly assigned one of three different doses of oral vinorelbine (30 or 40 or 50 mg).
      Treatment is administered three times a week (Monday, Wednesday and Friday) continuously
      until disease progression or unacceptable toxicity or to a maximum of 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to treatment failure</measure>
    <time_frame>TTF rates per arm will be compared at 4 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>Patients will be assessed every 2 months during the first 6 months on treatment and every 4 months thereafter until documentation of objective tumor progression or death.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>Patients will be assessed every 2 months during the first 6 months on treatment and every 4 months thereafter until documentation of objective tumor progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>Acute toxicity will be assessed during the first 8 weeks, sub-acute 8 weeks to 4 months, chronic post 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in blood concentrations of angiogenesis-associated surrogate markers and pharmacokinetics</measure>
    <time_frame>Baseline values will be assessed for predictive potential and assessment on weeks 2,4,8, 12 and thereafter every 2 months they will be analyzed for their capacity to act as surrogate markers of treatment activity</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Breast Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine oral formulation</intervention_name>
    <description>Patients will take three times a week [Monday, Wednesday and Friday] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Ages 16 - 75 years

          -  Genders: both

          -  Performance status 0-2 according to the World Health Organization (WHO) scale

          -  Life expectancy of at least 16 weeks

          -  Adequate bone marrow, hepatic and renal functions

          -  Absence of brain metastasis

          -  Metastatic/locally advanced refractory prostate, breast or non-small cell lung cancer
             previously treated with no more than two chemotherapeutic regimens

          -  White blood cells &gt;= 3500/mm^3

          -  Absolute neutrophil count &gt;= 1500/mm^3

          -  Platelets &gt;= 100,000/mm^3

          -  Total serum bilirubin less than 1.5 mg/dl

          -  Serum transaminases less than 2.0 x upper normal limit (UNL) unless attributed to
             liver metastases

          -  Serum creatinine within normal range

        Exclusion Criteria:

          -  Major active infection

          -  More than two prior chemotherapy regimens for metastatic disease

          -  Any of the following within the 12 months prior to starting the study treatment:

               -  myocardial infarction,

               -  severe/unstable angina,

               -  coronary/peripheral artery bypass graft,

               -  congestive heart failure,

               -  cerebrovascular accident or transient ischemic attack, or pulmonary embolism,

               -  cardiac dysrhythmias of grade &gt;/= 2,

               -  atrial fibrillation of any grade, or

               -  heart rate corrected interval (QTc) &gt; 450 msec for males or &gt; 470 msec for
                  females.

          -  Hypertension that cannot be controlled with medications (&gt; 150/100 mmHg despite
             optimal medical therapy)

          -  Ongoing anti-coagulation therapy

          -  Pregnancy or breastfeeding

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration; or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into the
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evangelos Briasoulis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Oncology, Medical School, University of Ioannina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Dunant Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Attikon&quot;</name>
      <address>
        <city>Athens</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agii Anargiri Cancer Hospital</name>
      <address>
        <city>Athens</city>
        <zip>13122</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hygeia Hospital</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chania</name>
      <address>
        <city>Chania</city>
        <zip>73300</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina, Medical Oncology Dept</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenio&quot; Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54007</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Papageorgiou&quot; Cancer Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>564 03</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2006</study_first_submitted>
  <study_first_submitted_qc>January 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>February 27, 2008</last_update_submitted>
  <last_update_submitted_qc>February 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Evangelos Briasoulis</name_title>
    <organization>Hellenic Cooperative Oncology Group</organization>
  </responsible_party>
  <keyword>Metronomic-therapy</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>Recurrent Breast Cancer</keyword>
  <keyword>Recurrent Non Small Cell Lung Cancer</keyword>
  <keyword>Metastatic prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

